The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Set Up Biologics Oversight Function within R&D Division in Order to Enhance Biopharmaceutical Research Level
March 5, 2013
- Teva Pharma, Nippon Kayaku Receive Approval of Japan’s Second G-CSF Biosimilar
March 5, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
March 4, 2013
- Pfizer Japan’s Ethical Drug Sales Dip 4.2% on Lipitor Patent Expiry: FY2012 Earnings
March 4, 2013
- Extra Concurrent-Use Indications Approved for DPP-4 Inhibitor Equa: Novartis
March 4, 2013
- Merck Serono Appoints Koichi Katsura as Head of R&D Japan
March 4, 2013
- Abilify Once-Monthly Injection Approved in US: Otsuka
March 4, 2013
- ARB Sales Apparently Peak Out in Japan Antihypertensive Market
March 1, 2013
- Astellas to Adopt International Financial Reporting Standards as of March 2014
March 1, 2013
- DSP’s US Subsidiary Sunovion Announces FDA Acceptance of NDA Resubmission for Epilepsy Treatment Stedesa
March 1, 2013
- Takeda to Develop New Compounds for Autoimmune Diseases Jointly with Resolve Therapeutics of US
March 1, 2013
- Taiho Files for Novel Anticancer Agent TAS-102 in Japan
March 1, 2013
- BMKK, Pfizer Japan Launch, Copromote Anti-Xa Agent Eliquis
March 1, 2013
- Shionogi Receives FDA Approval for Dyspareunia Treatment, Plans its Launch in June
February 28, 2013
- Gilenya Achieved Blockbuster Status in 2012; Canagliflozin Will Be Next: Pres. Tsuchiya of MTPC
February 28, 2013
- MTPC Files for Expanded Combination-Use Indication for DPP-4 Inhibitor Tenelia
February 28, 2013
- GSK Launches Anti-Malaria Drug Malarone in Japan
February 27, 2013
- Takeda Recalling Renal Anemia Drug Omontys in US after Death Reports
February 26, 2013
- Combined Sales of Januvia and Glactiv Break 110 Billion Yen in 2012: IMS Japan
February 26, 2013
- Janssen Files World’s 1st Application for Hepatitis C Treatment Simeprevir in Japan
February 26, 2013
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…